Bimekizumab Betters Plaque Psoriasis Clearance Versus Secukinumab at 48 Weeks


A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

Kristian Reich, MD, PhD

Kristian Reich, MD, PhD

Bimekizumab was associated with greater 100% skin clearance than comparator biologic secukinumab (Cosentyx) in both short-term and long-term treatment periods in new data from the phase 3b BE RADIANT trial.

In a UCB Pharma-funded study presented at the American Academy of Dermatology (AAD) 2021 Virtual Meeting Experience this weekend, investigators provided a comparison of the 2 interleukin-17 (IL-17) inhibitor biologic therapies for patients with moderate to severe plaque psoriasis.

The findings, conducted by Kristian Reich, MD, PhD, of the University Medical Center Hamburg-Eppendorf, and Richard B. Warren, MD, PhD, of the University of Manchester, show significant improvement in 100% Psoriasis Area Severity Index (PASI) scores at weeks 16 and 48 with bimekizumab. However, they also indicated a greater risk of oral candidiasis with investigative therapy.

Bimekizumab is a humanized monoclonal antibody which selectively inhibits the IL-17A and IL-17F pathway—both of which are believed to drive inflammation and plaque psoriasis pathobiology in affected patients. Comparatively, secukinumab only blocks the IL-17A pathway.

Investigators randomly assigned patients with moderate to severe plaque psoriasis 1:1 to either 320 mg bimekizumab every 4 weeks or 300 mg secukinumab once weekly for 4 weeks, followed by every 4 weeks. The trial treatment duration was 48 weeks.

Reich, Warren and colleagues sought a primary endpoint of PASI 100 from baseline at week 16 of treatment. Originally, the primary analysis sought the noninferiority of bimekizumab to secukinumab by -10 percentage points on PASI 100 prevalence, before being tested for treatment superiority.

Eligible patients were aged 18 years or older with plaque psoriasis for at least 6 months prior to screening, with moderate to severe disease defined as a PASI score of ≥12 at baseline, at least 10% body-surface area affected by psoriasis, and an Investigator’s Global Assessment (IGA) score of ≥3.

A total of 743 patients were assigned to either bimekizumab (n = 373) or secukinumab (n = 370). More than 60% (230 [61.7%]) of patients to receive bimekizumab achieved PASI 100 at week 16, versus just 48.9% (181) patients receiving secukinumab, indicating a 12.7 percentage-point adjusted-risk difference (95% CI, 5.8 – 19.6).

Investigators additionally observed a noninferiority and superiroirty to secukinumab (P <.001) based on this outcome.

By week 48, two thirds (67.0%) of patients treated with bimekizumab achieved PASI 100 response, while the rate of secukinumab-treated patients to achieve the mark had decreased to 46.2% (171). The adjusted risk difference increased to 20.9 percentage points in the extended time period (95% CI, 14.1 – 27.7; P <.001).

However, Riech, Warren and colleagues observed a significantly greater prevalence of oral candidiasis in the bimekizumab arm (72 [19.3%]) than the secukinumab arm (11 [3.0%]). All but 2 cases among the bimekizumab arm were mild or moderate in severity, and none led to treatment discontinuation.

Investigators concluded the data suggest IL-17A and IL-17F inhibition may be associated with greater clinical benefit in moderate to severe plaque psoriasis treatment than lone IL-17A inhibition.

Though the trial was limited by a lacking placebo group, insignificant patient racial diversity, and exclusion of IL-17 inhibitor-unresponsive patients, the team emphasized the BE RADIANT findings warrant a greater understanding of specific IL-17 pathway targeting in the treatment of plaque psoriasis.

“Longer and larger trials are required to determine the relative effects of interleukin-17A and interleukin-17F inhibition as compared with inhibition of interleukin-17A alone in psoriasis,” they wrote.

The study, “Bimekizumab versus Secukinumab in Plaque Psoriasis,” was published online in The New England Journal of Medicine.

Related Videos
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
© 2024 MJH Life Sciences

All rights reserved.